14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AGIO vs BHVN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Biohaven Ltd. (BHVN) is the stronger overall head-to-head candidate over Agios Pharmaceuticals, Inc. (AGIO) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). AGIO carries a Unified Composite Score of 55.9/100 (HOLD) at $30.56 (2.5x Forward P/E, -297.7% operating margin), whereas BHVN carries 42.1/100 (HOLD) at $13.95 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While AGIO currently prints a higher short-term Unified Composite Score (55.9/100 HOLD vs. BHVN 42.1/100 HOLD), BHVN captures the overall institutional head-to-head verdict (4–6 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -297.7% operating margin) and revenue trajectory (+0.0% vs. +330.0% YoY).
Technical & Structure Timing Caution: AGIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.8); meanwhile BHVN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AGIO vs BHVN. Trailing 12-month operating profitability (AGIO -297.7% vs BHVN 0.0%) and valuation multiples (AGIO 2.5x vs BHVN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $2.1B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AGIO vs BHVN Key Questions & Quantitative Answers
As of Nov 16, 2026, Biohaven Ltd. (BHVN) is the stronger overall head-to-head candidate over Agios Pharmaceuticals, Inc. (AGIO) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). AGIO carries a Unified Composite Score of 55.9/100 (HOLD) at $30.56 (2.5x Forward P/E, -297.7% operating margin), whereas BHVN carries 42.1/100 (HOLD) at $13.95 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While AGIO currently prints a higher short-term Unified Composite Score (55.9/100 HOLD vs. BHVN 42.1/100 HOLD), BHVN captures the overall institutional head-to-head verdict (4–6 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -297.7% operating margin) and revenue trajectory (+0.0% vs. +330.0% YoY). Technical & Structure Timing Caution: AGIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.8); meanwhile BHVN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AGIO leads the Growth & Scale pillar: AGIO posts +330.0% YoY revenue growth and +0.0% YoY earnings growth on $141M TTM revenue (N/A gross margin, -297.7% operating margin), compared with BHVN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AGIO generates $141M in USD-normalized revenue versus N/A for BHVN. In operating R&D and SG&A reinvestment, AGIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BHVN.
AGIO screens cheaper on headline valuation multiples. AGIO trades at 2.5x Forward P/E, 2.5x Trailing P/E, N/M PEG, and 13.5x EV/Revenue (unreported EBITDA margin), whereas BHVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AGIO (-33.0% ROE) versus BHVN (-799.5% ROE) capital efficiency.
In options market volatility and institutional positioning, AGIO carries 65.7% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.13β · 85% Vol realized risk). By comparison, BHVN carries 91.5% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.40β · 111% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.